Cytologic grading of primary malignant salivary gland tumors: A blinded review by an international panel.


Journal

Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453

Informations de publication

Date de publication:
06 2020
Historique:
received: 22 12 2019
revised: 11 02 2020
accepted: 18 02 2020
pubmed: 9 4 2020
medline: 24 11 2020
entrez: 9 4 2020
Statut: ppublish

Résumé

Fine needle aspiration (FNA) is commonly used for the preoperative evaluation of salivary gland tumors. Tumor grade is a key factor influencing clinical management of salivary gland carcinomas (SGCs). To assess the ability to grade nonbasaloid SGCs in FNA specimens, an international panel of cytopathologists convened to review and score SGC cases. The study cohort included 61 cases of primary SGC from the pathology archives of 3 tertiary medical centers. Cases from 2005 to 2016 were selected, scanned, and digitized. Nineteen cytopathologists blinded to the histologic diagnosis reviewed the digitized cytology slides and graded them as low, high, or indeterminate. The panelists' results were then compared to the tumor grades based on histopathologic examination of the corresponding resection specimens. All but 2 of the 19 (89.5%) expert panelists review more than 20 salivary gland FNAs per year; 16 (84.2%) of the panelists work at academic medical centers, and 13 (68.4%) have more than 10 years' experience. Participants had an overall accuracy of 89.4% in the grading of SGC cases, with 90.2% and 88.3% for low- and high-grade SGC, respectively. Acinic cell carcinoma and mucoepidermoid carcinoma had the highest degree of accuracy, while epithelial-myoepithelial carcinoma and salivary duct carcinoma had the lowest degree of accuracy. As expected, the intermediate-grade SGC cases showed the greatest variability (high-grade, 42.1%; low-grade, 37.5%, indeterminate, 20.4%). This study confirms the high accuracy of cytomorphologic grading of primary SGC by FNA as low- or high-grade. However, caution should be exercised when a grade cannot be confidently assigned.

Sections du résumé

BACKGROUND
Fine needle aspiration (FNA) is commonly used for the preoperative evaluation of salivary gland tumors. Tumor grade is a key factor influencing clinical management of salivary gland carcinomas (SGCs). To assess the ability to grade nonbasaloid SGCs in FNA specimens, an international panel of cytopathologists convened to review and score SGC cases.
METHODS
The study cohort included 61 cases of primary SGC from the pathology archives of 3 tertiary medical centers. Cases from 2005 to 2016 were selected, scanned, and digitized. Nineteen cytopathologists blinded to the histologic diagnosis reviewed the digitized cytology slides and graded them as low, high, or indeterminate. The panelists' results were then compared to the tumor grades based on histopathologic examination of the corresponding resection specimens.
RESULTS
All but 2 of the 19 (89.5%) expert panelists review more than 20 salivary gland FNAs per year; 16 (84.2%) of the panelists work at academic medical centers, and 13 (68.4%) have more than 10 years' experience. Participants had an overall accuracy of 89.4% in the grading of SGC cases, with 90.2% and 88.3% for low- and high-grade SGC, respectively. Acinic cell carcinoma and mucoepidermoid carcinoma had the highest degree of accuracy, while epithelial-myoepithelial carcinoma and salivary duct carcinoma had the lowest degree of accuracy. As expected, the intermediate-grade SGC cases showed the greatest variability (high-grade, 42.1%; low-grade, 37.5%, indeterminate, 20.4%).
CONCLUSION
This study confirms the high accuracy of cytomorphologic grading of primary SGC by FNA as low- or high-grade. However, caution should be exercised when a grade cannot be confidently assigned.

Identifiants

pubmed: 32267606
doi: 10.1002/cncy.22271
pmc: PMC7413070
mid: NIHMS1614065
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

392-402

Subventions

Organisme : NCI NIH HHS
ID : P01 CA240239
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2020 American Cancer Society.

Références

Am J Surg Pathol. 2019 Jul;43(7):885-897
pubmed: 31021855
ANZ J Surg. 2005 Mar;75(3):144-6
pubmed: 15777394
Diagn Cytopathol. 2017 Sep;45(9):808-819
pubmed: 28411379
Acta Cytol. 2013;57(6):567-74
pubmed: 24107383
Cytopathology. 2018 Aug;29(4):343-348
pubmed: 29683536
Am J Surg Pathol. 2018 Feb;42(2):e11-e27
pubmed: 29076877
Cancer Cytopathol. 2018 Feb;126(2):101-111
pubmed: 29131559
J Clin Epidemiol. 2013 Oct;66(10):1093-104
pubmed: 23958378
Otolaryngol Clin North Am. 2016 Apr;49(2):343-80
pubmed: 27040585
Diagn Cytopathol. 2015 Jun;43(6):495-509
pubmed: 25614439
Br J Oral Maxillofac Surg. 2010 Jan;48(1):26-9
pubmed: 19233526
J Oral Maxillofac Surg. 2010 Sep;68(9):2146-53
pubmed: 20580145
J Am Soc Cytopathol. 2019 May - Jun;8(3):157-164
pubmed: 31097292
Am J Clin Pathol. 2011 Oct;136(4):516-26
pubmed: 21917673
Cancer. 1992 Feb 1;69(3):615-9
pubmed: 1730113
Diagn Cytopathol. 2017 Dec;45(12):1088-1094
pubmed: 28960946
Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):720-3
pubmed: 12874071
Head Neck Pathol. 2009 Mar;3(1):69-77
pubmed: 20596994
Arch Pathol Lab Med. 2015 Dec;139(12):1525-30
pubmed: 26619024
Oncotarget. 2017 Jan 17;8(3):3946-3956
pubmed: 27992367
Cancer. 2004 May 1;100(9):1876-83
pubmed: 15112268
Patholog Res Int. 2014;2014:804265
pubmed: 25202469
Cancer Cytopathol. 2016 Jun;124(6):388-96
pubmed: 26959289
Cancers (Basel). 2019 Dec 01;11(12):
pubmed: 31805712
Cancer Cytopathol. 2018 Jul;126(7):490-497
pubmed: 29669190
J Oral Pathol Med. 2017 Mar;46(3):161-166
pubmed: 27230064
Cancer Cytopathol. 2017 Oct;125(10):757-766
pubmed: 28708928
Head Neck. 2008 Aug;30(8):1083-5
pubmed: 18528905
Head Neck. 2005 Mar;27(3):217-23
pubmed: 15672359
Cancer Cytopathol. 2018 Feb;126(2):94-100
pubmed: 29053216
Cancer Cytopathol. 2020 Feb;128(2):92-99
pubmed: 31742931
Ann Surg Oncol. 2013 Jul;20(7):2380-7
pubmed: 23440550
Diagn Cytopathol. 2020 Jan;48(1):17-29
pubmed: 31591825
Am J Surg. 1996 Dec;172(6):695-7
pubmed: 8988681
Adv Anat Pathol. 2019 Mar;26(2):84-92
pubmed: 30601148
Am J Clin Pathol. 2011 Jul;136(1):45-59
pubmed: 21685031
Mod Pathol. 2017 Jan;30(s1):S84-S95
pubmed: 28060371
Head Neck. 2014 Apr;36(4):517-23
pubmed: 23780687
Arch Otolaryngol Head Neck Surg. 1993 May;119(5):517-20
pubmed: 8484940
Diagn Cytopathol. 2019 Feb;47(2):67-87
pubmed: 30375201
Cancer. 2008 Oct 15;113(8):2082-9
pubmed: 18720358
Br J Cancer. 2003 Nov 3;89(9):1610-3
pubmed: 14583757
Int J Oral Maxillofac Surg. 2020 Feb;49(2):149-156
pubmed: 31375455
Diagn Cytopathol. 1991;7(3):267-72
pubmed: 1879262
Oral Maxillofac Surg. 2012 Mar;16(1):35-40
pubmed: 21894513
Head Neck Pathol. 2019 Sep;13(3):476-484
pubmed: 30887392
Oral Oncol. 2005 Nov;41(10):1021-7
pubmed: 16129655
Cancer Cytopathol. 2018 Jan;126(1):69-70
pubmed: 29165894
Cancer Cytopathol. 2020 Feb;128(2):87-88
pubmed: 31742900
Diagn Cytopathol. 2017 Sep;45(9):820-827
pubmed: 28371507
Diagn Cytopathol. 2000 Mar;22(3):139-46
pubmed: 10679992
Am J Surg Pathol. 2017 Aug;41(8):e33-e47
pubmed: 28614209
Head Neck Pathol. 2018 Dec;12(4):548-561
pubmed: 29524082

Auteurs

Daniel N Johnson (DN)

Department of Pathology, Cytopathology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Mine Onenerk (M)

Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey.

Jeffrey F Krane (JF)

Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Esther Diana Rossi (ED)

Department of Pathology, Fondazione Policlinico Universitario "Agostino Gemelli," IRCCS, Universita' Cattolica, Rome, Italy.

Zubair Baloch (Z)

Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania.

Güliz Barkan (G)

Loyola University Healthcare System, Maywood, Illinois.

Massimo Bongiovanni (M)

Department of Pathology, McGill University, Montreal, Quebec, Canada.

Fabiano Callegari (F)

Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.

Sule Canberk (S)

Cancer Signaling and Metabolism, Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.
Division of Cytopathology, Department of Pathology, Acibadem University, Istanbul, Turkey.

Glen Dixon (G)

HCA Laboratories, HCA Healthcare UK, London, United Kingdom.

Andrew Field (A)

Department of Pathology, St. Vincent Hospital, Sydney, Australia.

Christopher C Griffith (CC)

Cleveland Clinic Foundation, Cleveland, Ohio.

Nirag Jhala (N)

Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, Pennsylvania.

Sara Jiang (S)

Department of Pathology, Duke University Medical Center, Durham, North Carolina.

Daniel Kurtycz (D)

Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, State Laboratory of Hygiene, Madison, Wisconsin.

Lester Layfield (L)

Department of Pathology and Anatomical Services, University of Missouri, Columbia, Missouri.

Oscar Lin (O)

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Zahra Maleki (Z)

Division of Cytopathology, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland.

Miguel Perez-Machado (M)

Department of Cellular Pathology, Royal Free Hospital, London, United Kingdom.

Marc Pusztaszeri (M)

Department of Pathology, McGill University, Montreal, Quebec, Canada.

Philippe Vielh (P)

Department of Pathology, Laboratoire National de Santé, Dudelange, Luxembourg.

He Wang (H)

Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Matthew A Zarka (MA)

Department of Pathology and Laboratory Medicine, Mayo Clinic, Scottsdale, Arizona.

William C Faquin (WC)

Department of Pathology, Massachusetts General Hospital, Harvard School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH